This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2005 by Chiron Corporation.
Recruitment status was:  Active, not recruiting
Information provided by:
Chiron Corporation Identifier:
First received: December 2, 2005
Last updated: NA
Last verified: December 2005
History: No changes posted
The purpose of this study is to determine when a memory immune response after re-vaccination with Meningococcal C conjugate vaccine (Menjugate) or challenge with Meningococcal A/C polysaccharide vaccine can be observed, after initial vaccination with Meningococcal C conjugate vaccine during the UK immunization campaign

Condition Intervention Phase
Meningococcal Disease; Meningococcal Meningitis Biological: · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate®

Resource links provided by NLM:

Further study details as provided by Chiron Corporation:

Primary Outcome Measures:
  • To measure immunological memory response to N. meningitidis serogroup C after those who received a partial dose of Meningococcal A/C Polysaccharide vaccine and in subjects who received a dose of Chiron Meningococcal C conjugate vaccine.

Secondary Outcome Measures:
  • To assess the immunological response to N. meningitidis serogroup C in those challenged with meningococcal A/C polysaccharide vaccine and in those who received a dose of Chiron Meningococcal C conjugate vaccine.

Estimated Enrollment: 264
Study Start Date: September 2003

Ages Eligible for Study:   13 Years to 15 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Healthy adolescents between and including 13-15 years of age, who provide written informed consent and who received one immunization with Chiron Meningococcal C Conjugate vaccine (Menjugate) during the UK immunization campaign and for which documentation can be provided.

Exclusion Criteria:

  • Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262015

United Kingdom
University of Oxford, The Oxford Vaccine Group
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
Chiron Corporation
Principal Investigator: Andrew J. Pollard, MBBS, FRCPCH, PhD University of Oxford
  More Information Identifier: NCT00262015     History of Changes
Other Study ID Numbers: M14P2
Study First Received: December 2, 2005
Last Updated: December 2, 2005

Additional relevant MeSH terms:
Meningococcal Infections
Meningitis, Meningococcal
Central Nervous System Diseases
Nervous System Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Meningitis, Bacterial
Central Nervous System Bacterial Infections
Central Nervous System Infections
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017